Cargando…

73. Interim Resistance Analysis of Long-Acting Lenacapavir in Treatment-Naïve People with HIV at 28 Weeks

BACKGROUND: Lenacapavir (LEN) is a first-in-class HIV-1 capsid (CA) inhibitor in clinical development for treatment and prevention of HIV-1 infection. CALIBRATE is an ongoing, phase 2 clinical study evaluating subcutaneous (SC) or oral LEN, in combination with other antiretrovirals, in treatment-naï...

Descripción completa

Detalles Bibliográficos
Autores principales:	VanderVeen, Laurie, Margot, Nicolas, Naik, Vidula, Chang, Silvia, Martin, Ross, Dvory-Sobol, Hadas, Rhee, Martin, Callebaut, Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Oral Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643997/ http://dx.doi.org/10.1093/ofid/ofab466.073

Ejemplares similares

1581. Weight and Metabolic Changes with Long-Acting Lenacapavir in a Combination Regimen in Treatment-Naïve People with HIV-1 at Week 80
por: Kumar, Princy N, et al.
Publicado: (2023)

Long-acting lenacapavir acts as an effective preexposure prophylaxis in a rectal SHIV challenge macaque model
por: Bekerman, Elena, et al.
Publicado: (2023)

1585. Efficacy and safety of long-acting subcutaneous lenacapavir in heavily treatment-experienced people with multi-drug resistant HIV: Week 52 results
por: Ogbuagu, Onyema, et al.
Publicado: (2022)

1596. Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People with Multi-Drug Resistant HIV: Week 104 Results
por: Ogbuagu, Onyema, et al.
Publicado: (2023)

Lenacapavir: First Approval
por: Paik, Julia
Publicado: (2022)

Correction to: Lenacapavir: First Approval
por: Paik, Julia
Publicado: (2023)

Systemic Inflammation-Associated Proteins and Retinopathy of Prematurity in Infants Born Before the 28th Week of Gestation
por: Holm, Mari, et al.
Publicado: (2017)

Lenacapavir with Fostemsavir in a Multidrug-Resistant HIV-Infected Hemodialysis Patient
por: Bigirimana, Ferdinand, et al.
Publicado: (2023)

The Future of HCV Therapy: NS4B as an Antiviral Target
por: Dvory-Sobol, Hadas, et al.
Publicado: (2010)

Drug Interactions in Lenacapavir-Based Long-Acting Antiviral Combinations
por: Cilento, Maria E., et al.
Publicado: (2022)

Structural and Mechanistic Bases of Viral Resistance to HIV-1 Capsid Inhibitor Lenacapavir
por: Bester, Stephanie M., et al.
Publicado: (2022)

Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis
por: Lawitz, Eric, et al.
Publicado: (2015)

Long-acting lenacapavir protects macaques against intravenous challenge with simian-tropic HIV
por: Swanstrom, Adrienne E., et al.
Publicado: (2023)

Formation of DNA−Protein Cross-Links Between γ-Hydroxypropanodeoxyguanosine and EcoRI
por: VanderVeen, Laurie A., et al.
Publicado: (2008)

GS-CA1 and lenacapavir stabilize the HIV-1 core and modulate the core interaction with cellular factors
por: Selyutina, Anastasia, et al.
Publicado: (2021)

HIV Capsid Protein Genetic Diversity Across HIV-1 Variants and Impact on New Capsid-Inhibitor Lenacapavir
por: Troyano-Hernáez, Paloma, et al.
Publicado: (2022)

Disrupted Skeletal Muscle Mitochondrial Dynamics, Mitophagy, and Biogenesis during Cancer Cachexia: A Role for Inflammation
por: VanderVeen, Brandon N., et al.
Publicado: (2017)

The Impact of Immune Cells on the Skeletal Muscle Microenvironment During Cancer Cachexia
por: VanderVeen, Brandon N., et al.
Publicado: (2020)

Early Nutrition and Weight Gain in Preterm Newborns and the Risk of Retinopathy of Prematurity
por: VanderVeen, Deborah K., et al.
Publicado: (2013)

Crystalline cataract caused by a heterozygous missense mutation in γD-crystallin (CRYGD)
por: VanderVeen, Deborah K., et al.
Publicado: (2011)

Regulation of Skeletal Muscle DRP-1 and FIS-1 Protein Expression by IL-6 Signaling
por: Fix, Dennis K., et al.
Publicado: (2019)

1542. Impact of Subcutaneous Administration Sites on the Clinical Pharmacokinetics of Lenacapavir, a Long-Acting HIV Capsid Inhibitor: Does Body Site Matter?
por: Lat, Allen K, et al.
Publicado: (2023)

S73. EFFECT OF LURASIDONE ON COGNITION IN ADOLESCENTS WITH SCHIZOPHRENIA: INTERIM ANALYSIS OF A 2-YEAR OPEN-LABEL EXTENSION STUDY
por: Harvey, Philip D, et al.
Publicado: (2018)

MPS status report no. 222 Period 17.9.19 73 to 20.10.19 73 (Weeks 39-42)
por: Frammery, B
Publicado: (1973)

Highlights on the Development, Related Patents, and Prospects of Lenacapavir: The First-in-Class HIV-1 Capsid Inhibitor for the Treatment of Multi-Drug-Resistant HIV-1 Infection
por: Dzinamarira, Tafadzwa, et al.
Publicado: (2023)

Run 375P, 28.10.73: Resonance Excitation with 5C Line
por: Schnell, Wolfgang
Publicado: (1973)

Run 375P, 28.10.73: Resonance Excitation with 5C Line
por: Schnell, Wolfgang
Publicado: (1973)

Circulating Human Neonatal Naïve B Cells are Deficient in CD73 Impairing Purine Salvage
por: Pettengill, Matthew Aaron, et al.
Publicado: (2016)

Encephalitis with coinfection by Jamestown canyon virus (JCV) and varicella zoster virus (VZV)
por: VanderVeen, Nathan, et al.
Publicado: (2020)

The Acute Effects of 5 Fluorouracil on Skeletal Muscle Resident and Infiltrating Immune Cells in Mice
por: VanderVeen, Brandon N., et al.
Publicado: (2020)

Interim FDG-PET Scan in Hodgkin's Lymphoma: Hopes and Caveats
por: André, M., et al.
Publicado: (2011)

CD28 engagement inhibits CD73-mediated regulatory activity of CD8(+) T cells
por: Lai, Yo-Ping, et al.
Publicado: (2021)

Muscle wasting in cancer: opportunities and challenges for exercise in clinical cancer trials
por: Fairman, Ciaran M., et al.
Publicado: (2022)

1593. Switch to DOVATO in Patients Suppressed on Biktarvy (The SOUND Study), week 48 interim analysis
por: Slim, Jihad, et al.
Publicado: (2023)

P902: ISATUXIMAB, WEEKLY CARFILZOMIB AND DEXAMETHASONE AS SALVAGE THERAPY FOR RRMM; INTERIM RESULTS FROM A PHASE 2 TRIAL.
por: Vesole, David H., et al.
Publicado: (2023)

848. Approaches to Optimize Recruitment of Historically Underrepresented Black and Hispanic/LatinX MSM, Transgender, and Gender Non-binary Individuals into the Lenacapavir for PrEP (PURPOSE 2) Trial
por: Cespedes, Michelle, et al.
Publicado: (2021)

In vivo and in vitro Characterization of a Partial Mu Opioid Receptor Agonist, NKTR-181, Supports Future Therapeutic Development
por: Lee, Alex S., et al.
Publicado: (2021)

Interim Report
por: SSC. Central Design Group. USA
Publicado: (1985)

Compte rendu des reunions OAS 72 et 73 (28/1 et 8/2/82)
por: Boillot, J, et al.
Publicado: (1982)

Interim Report on the Examination of Corrosion Damage in Homes Constructed With Imported Wallboard: Examination of Samples Received September 28, 2009
por: Pitchure, D. J., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_fcvscoo4283o3kr8g7ke058jr4